Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Nov 5, 2026.

T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study

Adrienn Angyal, Stephanie Longet, Shona C Moore and 97 more

The Lancet Microbe · 2022 · CC BY

doi:10.1016/s2666-5247(21)00275-5

Abstract

Background. Previous infection with SARS-CoV-2 affects the immune response to the first dose of the SARS-CoV-2 vaccine. We aimed to compare SARS-CoV-2-specific T-cell and antibody responses in health-care workers with and without previous SARS-CoV-2 infection following a single dose of the BNT162b2 (tozinameran; Pfizer–BioNTech) mRNA vaccine.

Methods. We sampled health-care workers enrolled in the PITCH study across four hospital sites in the UK (Oxford, Liverpool, Newcastle, and Sheffield). All health-care workers aged 18 years or older consenting to participate in this prospective cohort study were included, with no exclusion criteria applied. Blood samples were collected where possible before vaccination and 28 (±7) days following one or two doses (given 3–4 weeks apart) of the BNT162b2 vaccine. Previous infection was determined by a documented SARS-CoV-2-positive RT-PCR result or the presence of positive anti-SARS-CoV-2 nucleocapsid antibodies. We measured spike-specific IgG antibodies and quantified T-cell responses by interferon-γ enzyme-linked immunospot assay in all participants where samples were available at the time of analysis, comparing SARS-CoV-2-naive individuals to those with previous infection.

Findings. Between Dec 9, 2020, and Feb 9, 2021, 119 SARS-CoV-2-naive and 145 previously infected health-care workers received one dose, and 25 SARS-CoV-2-naive health-care workers received two doses, of the BNT162b2 vaccine. In previously infected health-care workers, the median time from previous infection to vaccination was 268 days (IQR 232–285). At 28 days (IQR 27–33) after a single dose, the spike-specific T-cell response measured in fresh peripheral blood mononuclear cells (PBMCs) was higher in previously infected (n=76) than in infection-naive (n=45) health-care workers (median 284 [IQR 150–461] vs 55 [IQR 24–132] spot-forming units [SFUs] per 106 PBMCs; p<0·0001). With cryopreserved PBMCs, the T-cell response in previously infected individuals (n=52) after one vaccine dose was equivalent to that of infection-naive individuals (n=19) after receiving two vaccine doses (median 152 [IQR 119–275] vs 162 [104–258] SFUs/106 PBMCs; p=1·00). Anti-spike IgG antibody responses following a single dose in 142 previously infected health-care workers (median 270 373 [IQR 203 461–535 188] antibody units [AU] per mL) were higher than in 111 infection-naive health-care workers following one dose (35 001 [17 099–55 341] AU/mL; p<0·0001) and higher than in 25 infection-naive individuals given two doses (180 904 [108 221–242 467] AU/mL; p<0·0001).

Interpretation. A single dose of the BNT162b2 vaccine is likely to provide greater protection against SARS-CoV-2 infection in individuals with previous SARS-CoV-2 infection, than in SARS-CoV-2-naive individuals, including against variants of concern. Future studies should determine the additional benefit of a second dose on the magnitude and durability of immune responses in individuals vaccinated following infection, alongside evaluation of the impact of extending the interval between vaccine doses.

Funding. UK Department of Health and Social Care, and UK Coronavirus Immunology Consortium.

References 28

  1. 1.

    Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412-1423.

    Not in our library10.1056/nejmoa2101765

  2. 2.

    Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373.

    Not in our library10.1136/bmj.n1088

  3. 3.
    Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom · 2021
    No notice
  4. 4.

    Hall V, Foulkes S, Charlett A, et al. Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020. medRxiv. 2021.

    Not in our library10.1101/2021.01.13.21249642

  5. 5.

    Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021;397:1725-1735.

    Not in our library10.1016/s0140-6736(21)00790-x

  6. 6.

    Amanat F, Thapa M, Lei T, et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell. 2021;184:3936-3948.e10.

    Not in our library10.1016/j.cell.2021.06.005

  7. 7.
    Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern · 2021
    No notice
  8. 8.

    UK Department of Health & Social Care. Policy paper: UK COVID-19 vaccines delivery plan. Jan 13, 2021.

    Not in our library

  9. 9.

    Robertson JFR, Sewell HF, Stewart M. Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture? Lancet. 2021;397:879-880.

    Not in our library10.1016/s0140-6736(21)00455-4

  10. 10.

    Bradley T, Grundberg E, Selvarangan R, et al. Antibody responses after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021;384:1959-1961.

    Not in our library10.1056/nejmc2102051

  11. 11.
    Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection · 2021
    No notice
  12. 12.

    Ebinger JE, Fert-Bober J, Printsev I, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021;27:981-984.

    Not in our library10.1038/s41591-021-01325-6

  13. 13.
    Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals. · 2021
    Not checked
  14. 14.

    Buonfrate D, Piubelli C, Gobbi F, et al. Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study. Clin Microbiol Infect. 2021.

    Not in our library10.1016/j.cmi.2021.07.024

  15. 15.

    Manisty C, Otter AD, Treibel TA, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021;397:1057-1058.

    Not in our library10.1016/s0140-6736(21)00501-8

  16. 16.
    Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK · 2021
    Corrected
  17. 17.
    Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection · 2021
    No notice
  18. 18.

    Callaway E. Fast-spreading COVID variant can elude immune responses. Nature. 2021;589:500-501.

    Not in our library10.1038/d41586-021-00121-z

  19. 19.

    Claro IM, da Silva Sales FC, Ramundo MS, et al. Local transmission of SARS-CoV-2 lineage B.1.1.7, Brazil, December 2020. Emerg Infect Dis. 2021;27:970-972.

    Not in our library10.3201/eid2703.210038

  20. 20.

    Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384:1885-1898.

    Not in our library10.1056/nejmoa2102214

  21. 21.

    Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021;27:622-625.

    Not in our library10.1038/s41591-021-01285-x

  22. 22.
    Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera · 2021
    No notice
  23. 23.
    Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose · 2021
    No notice
  24. 24.

    Prendecki M, Clarke C, Brown J, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet. 2021;397:1178-1181.

    Not in our library10.1016/s0140-6736(21)00502-x

  25. 25.

    Mazzoni A, Di Lauria N, Maggi L, et al. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19. J Clin Invest. 2021;131.

    Not in our library10.1172/jci149150

  26. 26.

    Lozano-Ojalvo D, Camara C, Lopez-Granados E, et al. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals. Cell Rep. 2021;36.

    Not in our library10.1016/j.celrep.2021.109570

  27. 27.

    Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181:1489-1501.

    Not in our library10.1016/j.cell.2020.05.015

  28. 28.

    Tarke A, Sidney J, Methot N, et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Rep Med. 2021;2.

    Not in our library10.1016/j.xcrm.2021.100355

Cited by papers we hold 3

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.